Market Research Report
Asia Pacific DIABETES DRUGS MARKET FORECAST 2018-2026
|Published by||Inkwood Research||Product code||618293|
|Published||Content info||65 Pages
Delivery time: 1-2 business days
|Asia Pacific DIABETES DRUGS MARKET FORECAST 2018-2026|
|Published: April 9, 2018||Content info: 65 Pages||
Global vendors are expanding their business in APAC by establishing their manufacturing facilities in developing countries. As a result, the Asia-Pacific diabetes drug market is expected to exhibit the fastest CAGR of 10.81% over the forecast period of 2018-2026.
Several vendors are focusing on strategic collaborations with domestic distribution partners and suppliers to enhance their distribution and sales channels. The main focus is on Japan, India and China as these countries offer potential opportunities for many global vendors. Additionally, economic development and rise in healthcare spending are expected to further increase the demand for insulin delivery systems in APAC, benefiting the diabetes drug market. In India, diabetes has become a major health problem. Nearly half of the diabetic population goes undetected, resulting in complications at the time of diagnosis. On the other hand, in China, nearly 500 million people are believed to be pre-diabetic, and as a result, today, China is the biggest market for diabetes drugs in the Asia-Pacific market. Thus all these factors are collectively contributing to the APAC diabetes drug market's growth.
Companies like Pfizer, Sanofi, Eli Lilly And Company, Novo Nordisk A/S, GlaxoSmithKline, Macrogenics Inc, Xoma Corp, AstraZeneca Plc, Xeris Pharmaceuticals, B.Braun Melsungen Ag, Albireo Pharma Inc, Diavacs Inc and Astellas Pharma are operating in this market.